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Infection of ﬁsh with the facultative intracellular bacterium Francisella noatunensis remains an unre-
solved problem for aquaculture industry worldwide as it is difﬁcult to vaccinate against without using
live attenuated vaccines. Outer membrane vesicles (OMVs) are biological structures shed by Gram-
negative bacteria in response to various environmental stimuli. OMVs have successfully been used to
vaccinate against both intracellular and extracellular pathogens, due to an ability to stimulate innate,
cell-mediated and humoral immune responses. We show by using atomic force and electron microscopy
that the ﬁsh pathogenic bacterium F. noatunensis subspecies noatunensis (F.n.n.) shed OMVs both in vitro
into culture medium and in vivo in a zebraﬁsh infection model. The main protein constituents of the OMV
are IglC, PdpD and PdpA, all known Francisella virulence factors, in addition to the outer membrane
protein FopA and the chaperonin GroEL, as analyzed by mass spectrometry. The vesicles, when used as a
vaccine, reduced proliferation of the bacterium and protected zebraﬁsh when subsequently challenged
with a high dose of F.n.n. without causing adverse effects for the host. Also granulomatous responses
were reduced in F.n.n.-challenged zebraﬁsh after OMV vaccination. Taken together, the data support the
possible use of OMVs as vaccines against francisellosis in ﬁsh.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Francisella species (spp.) are non-motile, pleomorphic, Gram-
negative, strictly aerobic, facultative intracellular coccobacilli
(reviewed and described by Refs. [1,2], respectively). They are
extremely infectious, as less than 10 bacteria can establish disease
[3e5]. One member of the genus, Francisella noatunensis, has beennoatunensis; F.n.o., Francisella
s ssp. novicida; OMVs, outer
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0275 Oslo, Norway.
Ltd. This is an open access article ureported worldwide as a cause of francisellosis, a ﬁsh disease
resulting in large economic losses in the ﬁsh farming industry
[6e11]. F. noatunensis consists of two subspecies adapted to
different host temperatures. F. noatunensis ssp. orientalis (F.n.o.)
causes disease in ﬁsh living in warmer waters [6,7,9,11] and
F. noatunensis ssp. noatunensis (F.n.n.) causes disease in ﬁsh living in
colder waters [8,10,12]. Development of disease is more aggressive
for F.n.o. causing up to 95% mortalities in tilapia, while a normally
more chronic disease with varying mortality levels is observed for
F.n.n. (reviewed by Ref. [13]). This situation is comparable to the
human pathogenic bacterium Francisella tularensis, where different
subspecies vary in their virulence for humans (reviewed by
Ref. [14]). No commercial vaccine against ﬁsh francisellosis is
currently available [13,15], and attempts at using inactivated
whole-cell preparations of F.n.n. for vaccination of Atlantic cod
Gadus morhua L. has yielded unsatisfactory levels of protection [13].
The situation is similar to Francisella infections in humans, wherender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Experimental setup for infections and vaccination in adult zebraﬁsh AB wt.
Group Vaccine dose Challenge dose Number of ﬁsh infected
Dose-response experiment
PBS control e e 14
Low dose e 10^8 CFU 13
High dose e 10^9 CFU 15
Vaccination experiment
OMV þ PBS 40 mg e 17
OMV þ infected 40 mg 10^8 CFU 18
PBS þ infected e 10^8 CFU 18
Fig. 1. OMVs from F.n.n. contain numerous proteins associated with virulence. LC-
MS analysis of the most abundant proteins by Coomassie Blue stain identifying the
three Francisella pathogenicity island proteins IglC, PdpA and PdpD, the major outer
membrane protein FopA and the virulence-associated chaperonin GroEL. Arrowheads
indicate the protein band analyzed by LC-MS.
E. Brudal et al. / Fish & Shellﬁsh Immunology 42 (2015) 50e57 51vaccination with killed bacteria induces an antibody response with
only limited protection [16].
Production of membrane vesicles by cells is a conserved mech-
anism occurring throughout all domains of life [17]. In Gram-
negative bacteria, these vesicles are usually formed by budding
from the outer bacterial membrane. Outer membrane vesicles
(OMVs) are spherical, 10e300 nm in diameter, and contain outer
membrane components including LPS and periplasmic proteins.
Recent data indicates that they might also contain inner membrane
and cytoplasmic proteins in addition to DNA (e.g. Ref. [18]). The
protein content of OMVs show speciﬁc packaging, as some proteins
are enriched and some are excluded [19,20], though the exact
mechanism is not known. Many pathogenic bacteria incorporate
virulence factors, including toxins, into their OMVs [19e21],
enabling their delivery to distant host cells. Vaccines against many
extracellular bacterial pathogens have successfully been made by
inactivating whole bacteria commonly mixed with an oil-adjuvant
and administration by intraperitoneal (i.p.) injections. Other routes
of delivery and methods of formulation are also being used
(reviewed by Ref. [15]). In contrast, such vaccines are not sufﬁciently
effective against intracellular pathogens as protection is usually not
only dependent on humoral immunity, but also need to stimulate a
cellular mediated response. Vaccines based on a live attenuated
vaccine strain (LAV) generally induce the best protection [22]. LAV is
most efﬁciently constructed by gene technology (GMO). While LAV
and LAV-GMO are used for vaccination against both viral and bac-
terial infections in humans, there is an urgent need for solid,
extensive documentation of the safe use of such agents driving the
development cost. In particular, the utilization of GMO for vacci-
nation of ﬁsh, followed by its release into open water ﬁsh farms is
highly restricted. The use of OMV in vaccination against intracellular
bacterial pathogens in ﬁsh could overcome this problem. OMVs
derived from many pathogenic bacteria have shown protective ef-
ﬁcacy as vaccines [24e30] and immunization of humans using
OMVs has been performed with success against Neisseria meningi-
tidis type B [23,31]. Furthermore, OMVs induce both B- and T-cell
responses [24,32] which enable the induction of protective immu-
nity against typical intracellular pathogens, while avoiding prob-
lems regarding safety and licensing associated with LAV.
F. tularensis ssp. has previously been shown to produce vesicles in
cultured macrophages [33,34] and recent work reports that similar
vesicles could be isolated from broth cultured F. tularensis ssp. nov-
icida (F.t.n.) and Francisella philomiragia [35]. Mice macrophages
treated with OMVs released proinﬂammatory cytokines, and mice
vaccinated with OMVs were protected against subsequent challenge
with F.t.n. [35,36]. Electron microscopy studies revealed that F.n.n.
released vesicles in in vitro infected cod macrophages [2]. These
authors hypothesized that the formation of vesicles from F.n.n. was
exclusively an intracellular event as they were unable to detect
vesicles from extracellularly cultured bacteria. Here, we show that
intact OMVs can be isolated from broth-cultured F.n.n., that the
OMVs contains known immunogenic virulence factors and that
OMVs reduce progression of francisellosis in a zebraﬁsh infection
model. In addition, we show that F.n.n.-OMVs are produced in
zebraﬁsh embryos during infection, and that adult zebraﬁsh can be
used as a convenient model for infection studies with F.n.n.
2. Materials & methods
2.1. Strains, media and growth conditions
Cultivation of F.n.n. NCIMB14265T isolated from diseased
Atlantic cod G. morhua L. in Norway [8] was performed on Eugon
Chocolate Agar (ECA) or in Eugon Broth supplemented with 2 mM
FeCl3 (EBF) as previously described [37].2.2. Isolation of OMVs
For small scale experiments, 10 ml overnight cultures of F.n.n.
were used to inoculate 100 ml EBF to OD600 z 0.1, and grown to
late-logarithmic or early stationary growth phase [38]. The bacteria
were pelleted at 15,000 g at 4 C for 10 min. The supernatant was
sequentially ﬁltered through 0.45-mm and 0.2-mm ﬁlters and the
OMVs were isolated by ultracentrifugation at 125.000 g in principle
as described by Pierson et al. [35]. OMVs were resuspended in PBS,
and protein concentration was measured using a NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies Inc.). 25 ml ali-
quots were stored at 80 C for long-term storage. One aliquot was
spread on an ECA plate and incubated at 20e22 C for at least three
weeks to ensure sterility. For large-scale production 420 ml ﬁltered
OMV-containing supernatant was used.
2.3. SDS-PAGE and LC-MS/MS
Aliquots of OMVs were separated by SDS-PAGE followed by
Coomassie-Blue staining. The bands of interest were cut from the
gel, and the destaining and digestion protocol described by Aas
et al. [39] was used for in-gel trypsination. Desalting by solid phase
extraction and LC-MS/MS data acquisition and analysis was
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proteins, the FASTA ﬁle uniprot-Francisella containing 21,132 se-
quences was used.2.4. Microscopic analysis of OMVs
For Atomic Force Microscopy (AFM) imaging, MgCl2 was added
to a ﬁnal concentration of 10 mM to an aliquot of isolated OMVs,
and 10 ml of the suspension was applied to a freshly cleaved mica
surface. AFM was performed with a NanoWizard AFM (JPK) as
described by Bjelland et al. [41]. The theoretical sizes of OMVs were
calculated according to Pierson et al. [35]. For calculation of the
volume of nanotubes it was assumed that when nanotubes adhere
tomica they form the shape of half a cylinder. Volume calculation of
half a cylinder is based on V ¼ pr2h/2 where r ¼ measured height
and h ¼ measured length.
For transmission electron microscopy (TEM) carbon coated
Formvar copper grids were pretreated with poly-L-lysine for 15 min
and washed three times with MQ water. The grids were incubated
on an OMV solution for ﬁve minutes and washed three times with
PBS. Subsequently, the samples were ﬁxed in 1% glutaraldehyde for
4 min, washed three times with PBS, two times with MQ water,
negatively stained for 1 min with 4% uranyl acetate and washedFig. 2. Microscopic analysis of OMVs secreted from F.n.n. (AeC) OMVs isolated from cu
amplitude images of OMVs revealing numerous OMVs and thin projections connecting the
infected zebraﬁsh embryo revealing bacteria next to an OMV in an intracellular compartmen
bacteria surrounded with OMVs in an infected zebraﬁsh embryo. G) In vivo budding of OM
white arrows indicate OMVs, and arrowheads indicate nanotubes.once with MQ water. The grids were viewed in a Philips CM200
transmission electron microscope.
2.5. Preparation of bacterial cultures and zebraﬁsh embryo
infections
Preparation of bacterial suspensions, calculation of CFU and
infection of zebraﬁsh embryos was performed as previously
described [42]. At 7 d.p.i. the embryos were euthanized and ﬁxed in
10% buffered formalin. Whole zebraﬁsh embryos were embedded
in EPON resin and ultrathin-sections performed on a LEICAUltracut
UCT microtome. Sections were post-stained with uranyl acetate
and analyzed by TEM as described in 2.4.
2.6. F.n.n. infections of adult zebraﬁsh
Male and female Zebraﬁsh Danio reriowild type strain AB 10e11
months of age were obtained from the Alestr€om Zebraﬁsh Lab fa-
cility at the Norwegian University of Life Sciences and kept in 6 L
sized ﬁsh tanks. Fish were fed daily with standard feed for Zebraﬁsh
husbandry (SDS 400 Scientiﬁc Fish Food). The ﬁsh were acclima-
tized to room temperature (20 ± 2 C) at least one week prior to
injections, and 50% water was changed twice daily. The following
water parameters were monitored using commercial test kitslture supernatant, and (DeG) OMVs secreted within zebraﬁsh embryos. A þ B) AFM
OMVs (A) in addition to a nanotube (B). C) TEM of OMVs and nanotubes. D) TEM of an
t. E) TEM of zebraﬁsh embryo cells heavily infected with bacteria F) TEM of extracellular
V in the cytoplasm of an infected zebraﬁsh embryo. Asterisks indicate F.n.n., black and
E. Brudal et al. / Fish & Shellﬁsh Immunology 42 (2015) 50e57 53(TetraTest kit): water hardness, pH, NO2, NO32, NH3/NH4þ and O2.
Experimental setup is described in Table 1. The ﬁsh were anes-
thetized with Tricaine methanesulfonate (MS-222, SigmaeAldrich)
100 mg/L before intraperitoneal (i.p.) injections were performed as
described by Cosma et al. [43] using PBS or different amounts of
F.n.n. resuspended in PBS (Table 1). All i.p. injections were per-
formed with a volume of 25 ml. Mortality was recorded twice daily,
and moribund ﬁsh were euthanized with 300 mg/L Tricaine
methanesulfonate. For the vaccine experiment, the ﬁsh were
immunized once with either 40 mg OMVs in PBS or PBS without
antigen by i.p. injection. The ﬁsh were challenged by i.p. injection
after an immunization period of 32 days (637 degree-days) with a
challenge dose of 10^ 8 CFU F.n.n. or PBS lacking bacteria. The
challenge dose selected for the vaccine experiment was chosen in a
desire to avoid an acute model of infection and instead mimic the
naturally occurring disease, as francisellosis in Atlantic cod is a
chronic, granulomatous disease [8,12].2.7. Quantiﬁcation of bacterial burden
For the doseeresponse experiment, three randomly chosen ﬁsh
from each group were euthanized at each time point. For the
vaccination experiment, the number of ﬁsh at each time point was
4. Necropsy was performed on all euthanized ﬁsh, and the spleen,
heart and kidney harvested, transferred to RNAlater (Ambion) and
stored at 4 C until further processing. The tissue was homogenized
using QIAGEN TissueLyser II at 15 Hz for 20 s in 100 ml lysis buffer
with 20 mg/ml lysozyme (SigmaeAldrich) and genomic DNA
(gDNA) extracted with the QIAGEN DNAasy Blood & Tissue Mini kit
according to the manufacturers instructions. Genomic DNA (gDNA)
was eluted in 100 ml DEPC treated H2O, and diluted 1:10 in DEPC
H2O before 5 ml was used as template for quantitative PCR (qPCR).
The previously published diagnostically validated primer pair
[44] was chosen for absolute quantiﬁcation of the amount of F.n.n.
genome equivalents (GE) in each ﬁsh tissue. Quantitative PCR was
performed in 20 ml volume in triplicates as modiﬁed from Ref. [45]
using Express SYBR GreenER qPCR Supermix Universal (Life Tech-
nologies Inc.) and a Stratagene Mx3005p qPCR machine. The
cycling conditions and determination of primer binding efﬁciency
from zebraﬁsh gDNA was performed as described by Duodu et al.
[44]. 1 ng of F.n.n. gDNA was used as equilibrator on each qPCR
plate, and absolute quantiﬁcation was performed under the
assumption that 20 fg gDNA corresponds to 10 Genome Equivalents
(GE) for F.n.n. [44].Fig. 3. Cumulative survival of adult zebraﬁsh infected with F. noatunensis ssp. noatunens
(:) showing a clear doseeresponse with regards to mortality (p-value 0.0111 Wilcoxon
between the groups infected with 10^8 CFU or PBS (p-value 0.1359 Wilcoxon test, p-value 0.1
sampled for quantiﬁcation of bacterial burden and the infection experiment was terminate
10 8^ CFU (-), vaccinated with 40 mg OMVs and mock-infected with PBS (:), or mock-va
mortality between the groups were observed. Arrows indicate time of sample collections f2.8. Histology
Three randomly chosen ﬁsh from each groupwere euthanized at
four w.p.i., ﬁxed in 10% buffered formalin and processed routinely
[46] for longitudinal whole-sections.
2.9. Statistical analysis
Statistical analysis of the data sets was performed using JMP
8.0.2. (SAS Institute Inc., Cary, NC, USA). KaplaneMeier survival
analysis [47] was used for analyzing survival, and differences be-
tween groupswere deemed statistically signiﬁcant if p-value < 0.05
using Wilcoxon-test and Log-rank test. Differences in bacterial
quantiﬁcation between groups were deemed statistically signiﬁ-
cant if p < 0.05 using a one-tailed Student's t-test assuming unequal
variance. The relative bacterial burden between vaccinated and
unvaccinated infected groups was calculated for each tissue and
time point.
3. Results and discussion
3.1. F.n.n. produced large amounts of OMVs in liquid culture
During investigation of protein secretion systems of F.n.n., it was
discovered that the bacterium secreted large amounts of OMVs into
the supernatant of broth cultures. From 420 ml of late-log/early
stationary liquid culture of F.n.n. an average of 1.8 mg (SD 390 mg,
n ¼ 3) protein was recovered, corresponding to 4.37 mg protein/ml
culture. Under the same growth conditions the corresponding
value was 0.06 mg/ml for F. philomiragia. It is interesting to note that
Pierson et al. [35] obtained 86 mg OMV protein yield from 350 ml
culture under optimized OMV producing growth conditions for
F.t.n. The OMVs were isolated by the same method as described by
Pierson et al. [35], and not by ﬂotation through a density gradient
[36], which could inﬂuence the ﬁnal yield. Systematic investigation
of optimal conditions for F.n.n. OMV isolation was not performed,
though increased OMV yields at later growth stages (late-log/early
stationary) compared to mid-log was observed (data not shown).
3.2. OMVs contain numerous proteins associated with virulence
Several abundant proteins were detectable by Coomassie Blue
staining after separation of the puriﬁed supernatant by SDS-PAGE
(Fig. 1). Five of the most abundant proteins were analyzed by LC-
MS. Three proteins, IglC, PdpD and PdpA are all associated with
the Francisella pathogenicity island (FPI), where the most abundantis. A) Adult zebraﬁsh AB wt infected with PBS (C), 10^8 CFU F.n.n. (-) or 10^9 CFU F.n.n.
test, p-value 0.0142 Log-rank test). No statistical signiﬁcant mortality was observed
297 Log-rank test). At 14 dpi, all remaining ﬁsh in the high infection group (n ¼ 3) were
d. B) Survival of adult Zebraﬁsh AB wt vaccinated with 40 mg OMVs and infected with
ccinated with PBS and infected with 10^8 CFU F.n.n. (C). No signiﬁcant differences in
or quantiﬁcation experiments.
Fig. 4. Reduction of bacterial burden in vaccinated ﬁsh. A) Absolute quantiﬁcation of
F.n.n. genome equivalents (GE) in kidney of infected zebraﬁsh, showing reduced bac-
terial burden in ﬁsh vaccinated with OMVs at 1 w.p.i. (p-value 0.076), 2 w.p.i. (p-value
0.0425) and 4 w.p.i. (0.096). BeC) Absolute quantiﬁcation of F.n.n. GE in B) spleen and
C) heart failing to achieve statistical signiﬁcance for reduction of bacteria in vaccinated
ﬁsh (p-values 0.1341, 0.0991 and 0.1065 for spleen 1, 2 and 4 w.p.i., and 0.2355, 0.0799
and 0.3112 for heart). Values are given as geometrical mean þ SEM. Stars denote
statistical signiﬁcant difference with p-value < 0.05.
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two others were the major outer membrane protein (FopA) and a
chaperonin (GroEL) (Supplementary Figs. 1e5). Interestingly, all of
the identiﬁed F.n.n.-OMV proteins have previously been identiﬁed
as components of F.t.n. and/or F. philomiragia OMVs [35,36]. Several
additional weaker bands present in the sample were not analyzed,
and although not investigated the OMVs probably contain LPS O-
antigen due to their budding from the bacterial outer membrane. A
recombinantly expressed IglC protein delivered through an atten-
uated Listeria monocytogenes strain [48] and LPS O-antigen subunit
vaccines [49] has previously been shown to afford some protection
against infection with F. tularensis indicating their importance as
constituents of F.n.n.-OMVs.
3.3. Intact OMVs were isolated and veriﬁed by microscopic analysis
Atomic Force Microscopy (AFM) and Transmission Electron
Microscopy (TEM) analysis were performed to verify the size,
morphology and integrity of the isolated OMVs (Fig. 2(AeC)). In
addition to the numerous and intact OMVs of spherical shape
clearly visible by AFM and TEM analysis, a few nanotubes [36] were
observed. The mean diameter of OMVs from F.n.n. was 72.34 nm
(SD¼ 26.17), the median diameter was 67.32 nm, and themeasured
size range was 24e133 nm. This corresponds well with published
data for OMVs from F.t.n. (97 nm) and F. philomiragia (76 nm) [35].
Observed nanotubes (Fig. 2(B)) were measured as 800e1000 nm in
length, 11e18 nm in height and a width of 100e120 nm, and would
have a mean diameter of 50.7 nm as perfect spheres, supporting a
hypothesis that nanotubes and OMVs are the same biological
structures with different conformations [36].
3.4. OMVs were produced in vivo in infected zebraﬁsh embryos
To investigate secretion of OMV from F.n.n.within host tissuewe
took advantage of our previously developed zebraﬁsh embryo
model for Francisella infections [42]. TEM images of infected
zebraﬁsh embryos revealed intracellular bacteria in infected cells
(Fig. 2(D, E)) and in the extracellular milieu (Fig. 2(F)), verifying
previous observations by ﬂuorescence microscopy [42]. Some host
cells were heavily infected and were in various stages of cell death
(Fig. 2(E)), while others (such as endothelial cells) did not appear to
be affected (data not shown). OMVs could be observed in the near
vicinity of intracellular bacteria, as previously observed using
Atlantic cod primarymacrophages [2]. However, in contrast to their
results we also observed OMVs in the near vicinity of extracellular
and in vitro grown bacteria (Fig. 2(F)). The discrepancy between
these studies could be due to the use of different growthmedium as
OMV production is inﬂuenced in response to various environ-
mental stimuli [21]. Here F.n.n. was grown in Bacto Eugon Broth
supplemented with 2 mM FeCl3, while broth medium (PHARMAQ
AS) was used in the previous study [2]. In rare events OMVs could
be observed budding from the outer membrane of the bacteria in
vivo (Fig. 2(G)).
3.5. F.n.n. caused dose-dependent mortality of adult zebraﬁsh
It has previously been described that adult zebraﬁsh are sus-
ceptible to i.v. infection with F.n.o. [50], and susceptibility to i.v.
infection with F.n.n. has been demonstrated in a zebraﬁsh embryo
model [42]. However, the susceptibility of adult zebraﬁsh towards
infection with F.n.n. had not been investigated. When infecting
adult zebraﬁsh with 10^ 9 CFU of F.n.n., the onset of mortality
occurred at 2 d.p.i., while there was an initial delay in onset of
mortality for the group infected with 10^8 CFU, starting at 4 d.p.i.
(Fig. 3(A)). No mortality was observed in the PBS injected controls.All infected ﬁsh exhibited decreased appetite and decreased
motility, and moribund ﬁsh displayed erratic swimming behavior.
Signiﬁcant difference in survival between groups infected with
10 9^ and 10^8 CFU was observed. For the 10 8^ infection dose after
an initial acute phase of infection, no more mortality was
observed. The infection entered a chronic state similar to that
observed in Atlantic cod infected with F.n.n. [12]. Zebraﬁsh appears
to be less susceptible to acute mortality caused by F.n.n. compared
to F.n.o. as 10^ 6 CFU F.n.o. injected intraperitoneal caused 100%
mortality in a previous study [50] while 10^ 8 CFU F.n.n. caused
only low levels of acute mortality in this study. Thus, embryo and
adult zebraﬁsh display similar susceptibility to F.n.n. and F.n.o
infections.
Fig. 5. Histological examination of infected zebraﬁsh. A) Kidney of PBS control, 40 magniﬁcation. B) Kidney of PBS mock-vaccinated ﬁsh challenged with 10^8 CFU F.n.n., 40
magniﬁcation. C) Liver of PBS mock-vaccinated ﬁsh challenged with 10^8 CFU F.n.n., 10 magniﬁcation. D) Kidney of OMV vaccinated ﬁsh challenged with 10^8 CFU .n.n., 40
magniﬁcation.
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development of francisellosis in zebraﬁsh upon subsequent
challenge with F.n.n.
Of 36 OMV vaccinated zebraﬁsh only one exhibited complica-
tions after vaccination. Shortly after vaccination this ﬁsh developed
problems with keeping aﬂoat in the water and was euthanized due
to ethical considerations. Upon necropsy, inﬂammation and deﬂa-
tion of the anterior segment of the swim bladder was evident,
probably caused by injection in or close to the swim bladder. No
other evidence of discomfort due to vaccination was observed in
any other ﬁsh. The ﬁshwere eating and behaving normally from the
ﬁrst day after vaccination. The ﬁsh was vaccinated with OMVs
puriﬁed with the same method as described by Pierson et al. [35]
and may contain traces of cell debris. Such impurities are possible
to remove by ﬂotation through a density gradient [36]; however
this would enhance the cost of OMV production bymagnitudes and
would not be suitable for vaccination of ﬁsh in aquaculture. Still, it
can be concluded that the OMVs are safe for immunization in the
adult zebraﬁsh.
32 days after immunization the ﬁsh were infected with either
10^ 8 CFU of F.n.n. or with PBS (for the uninfected controls). The 10^8
infection dose was chosen to mimic the natural pathogenesis of the
natural cod host. Only one non-speciﬁc mortality occurred during
the ﬁrst day in the vaccinated group (Fig. 3(B)).
Unvaccinated þ infected ﬁsh exhibited anorexia and decreased
motility for the ﬁrst two weeks of the experiment verifying the
results of the previous infection experiment (Fig. 3(A)). These
symptoms are similar to what is observed in Atlantic cod infected
with F.n.n. [8,12]. While the vaccinated þ infected ﬁsh had an initial
slight decrease in appetite the ﬁrst days after infection, this effect
was reduced compared to the unvaccinated group and completely
restored from 4 d.p.i. The vaccinated þ uninfected control group
exhibited no clinical symptoms throughout the experiment. As
bacterial growth by CFU counts does not give reliable estimates for
F.n.n., bacterial organ burden was investigated by qPCR (42). Fewer
bacteria were detected in all tissues in vaccinated compared tounvaccinated ﬁsh, although the difference was only statistically
signiﬁcant in kidney (Fig. 4(AeC)). The amount of bacteria declined
throughout the experiment for all groups, but vaccinated ﬁsh
consistently yielded lower organ burden. The results indicate that
the a cellular F.n.n.-derived OMV vaccine formulation induced some
protection in zebraﬁsh against subsequent F.n.n infections. Vacci-
nating against intracellular pathogens such as Francisella has al-
ways been a challenge, especially without resorting to the use of
live-attenuated vaccines (LAVs) [51]. The reason is probably due
to the need for stimulation of cell-mediated immunity [16], in
which vaccines based on killed whole-cells or protein subunits
generally has low efﬁcacy [51]. Efﬁcacy of OMVs for inducing pro-
tective immunity against other typical intracellular bacterial
pathogens has previously been shown for e.g. Salmonella, Bur-
kholderia, Brucella [24,27,30] and F.t.n. [35,36]. Therefore, OMVs
should be considered as an alternative vaccination approach
against this kind of pathogens, and may apply to vaccination
against francisellosis in Atlantic cod.
The effect of vaccination was estimated by quantiﬁcation of
bacterial burden by qPCR as estimation by CFU counting for F.n.n.
has proven challenging, e.g., the bacterium is inhibited by the
presence of other bacteria [13]. Selective media has been described
for isolation of F.n.n. but this method has been unreliable for esti-
mation of bacterial burden. Even pure broth-cultured F.n.n. plated
on antibiotic-containing media resulted in highly variable CFU es-
timates. Previous studies using mycobacteria has shown a strong
correlation between quantiﬁcation of bacteria using qPCR and CFU
[52,53], though distinguishing between live and dead bacteria is
problematic by thismethod due to potential persistence of genomic
DNA after bacterial death.
3.7. F.n.n. induced a granulomatous response in zebraﬁsh which
was reduced by vaccination with OMVs
To verify that F.n.n.was able to establish chronic infections in the
model host zebraﬁsh histological examination of longitudinal sec-
tions at 4 w.p.i. was performed. The histology revealed formation of
E. Brudal et al. / Fish & Shellﬁsh Immunology 42 (2015) 50e5756granulomas in the kidney, liver and the abdominal cavity of all
infected ﬁsh investigated (Fig. 5). Some granulomas were also
present in OMV vaccinated ﬁsh, however, the response seemed
milder and the granulomas more organized (Fig. 5(D)). No granu-
lomas were evident in PBS injected ﬁsh. A granulomatous response
to infectionwith F.n.n. is similar to naturally occurring francisellosis
in Atlantic cod [8,12] further indicating the applicability of zebraﬁsh
as a model for studying F.n.n..
4. Conclusions
OMVs containing known virulence factors can be isolated from
F.n.n., and induces protective immunity against francisellosis in a
zebraﬁsh infection model. Further studies are required to investi-
gate whether this also applies for Atlantic cod. Nonetheless,
vaccination with OMVs represents a promising approach to protect
ﬁsh against disease caused by Francisella spp. without resorting to
LAVs, thereby circumventing potential problems regarding safety
and legislation.
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